Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hessamoddin Roustaei

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Data in Brief|June 29, 2023
A dataset of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT images of patients with high-grade GliomaHessamoddin Roustaei, Nasim Norouzbeigi, Habibeh Vosoughi, et al.
Clinical Nuclear Medicine|March 11, 2024
Nonmalignant 68 Ga-FAPI-46 Uptake in 2 Cases of TENIS Syndrome : Comparison With 18 F-FDGFarivash Karamian, Ramin Sadeghi, Atena Aghaee, et al.
Contrast Media & Molecular Imaging|March 14, 2022
Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Hessamoddin Roustaei, Zahra Kiamanesh, Emran Askari, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|June 16, 2023
[<sup>68</sup>Ga] Ga-Pentixafor diffuse bilateral Adrenal & Breast uptake in a patient with High-grade Glioma: A note of caution on normal variantsHessamoddin Roustaei, Emran Askari, Somayeh Barashki, et al.
International Journal of Molecular Sciences|October 23, 2021
Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [<sup>18</sup>F]F-FDG in Oncology: A Systematic ReviewGiorgio Treglia, Barbara Muoio, Hessamoddin Roustaei, et al.
Diagnostics (Basel, Switzerland)|October 16, 2024
Superscan Pattern on Bone Scintigraphy: A Comprehensive ReviewEmran Askari, Sara Shakeri, Hessamoddin Roustaei, et al.
European Journal of Radiology|August 30, 2024
[<sup>68</sup> Ga]Ga-CXCR4 PET/CT imaging in high-grade glioma for assessment of CXCR4 receptor expressionHessamoddin Roustaei, Habibeh Vosoughi, Emran Askari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Diagnostic Performance of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsChristian Uprimny, Elisabeth von Guggenberg, Anna Sviridenko, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Data in Brief|June 29, 2023
A dataset of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT images of patients with high-grade GliomaHessamoddin Roustaei, Nasim Norouzbeigi, Habibeh Vosoughi, et al.
Clinical Nuclear Medicine|March 11, 2024
Nonmalignant 68 Ga-FAPI-46 Uptake in 2 Cases of TENIS Syndrome : Comparison With 18 F-FDGFarivash Karamian, Ramin Sadeghi, Atena Aghaee, et al.
Contrast Media & Molecular Imaging|March 14, 2022
Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Hessamoddin Roustaei, Zahra Kiamanesh, Emran Askari, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|June 16, 2023
[<sup>68</sup>Ga] Ga-Pentixafor diffuse bilateral Adrenal & Breast uptake in a patient with High-grade Glioma: A note of caution on normal variantsHessamoddin Roustaei, Emran Askari, Somayeh Barashki, et al.
International Journal of Molecular Sciences|October 23, 2021
Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [<sup>18</sup>F]F-FDG in Oncology: A Systematic ReviewGiorgio Treglia, Barbara Muoio, Hessamoddin Roustaei, et al.
Diagnostics (Basel, Switzerland)|October 16, 2024
Superscan Pattern on Bone Scintigraphy: A Comprehensive ReviewEmran Askari, Sara Shakeri, Hessamoddin Roustaei, et al.
European Journal of Radiology|August 30, 2024
[<sup>68</sup> Ga]Ga-CXCR4 PET/CT imaging in high-grade glioma for assessment of CXCR4 receptor expressionHessamoddin Roustaei, Habibeh Vosoughi, Emran Askari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 28, 2025
Diagnostic Performance of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine TumorsChristian Uprimny, Elisabeth von Guggenberg, Anna Sviridenko, et al.
Pageof 1